[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coagulation-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coagulation-defect":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100622468","study-protocol-impact-of-metamizole-optalgin-on-anti-xa-concentrations-in-oncology-patients-receiving-doacs-100622468",false,"NCT07384013","Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs","Inclusion Criteria:\n\n* Adult oncology patients (≥18 years old).\n* Receiving apixaban or rivaroxaban for anticoagulation.\n* New\u002Fcurrent metamizole users taking at least 1g TID for pain management.\n* Platelets ≥100×10⁹\u002FL\n* ECOG PS\\\u003C3\n* Provided informed consent\n\nExclusion Criteria:\n\n* History of allergic reaction to metamizole or DOACs.\n* Individuals with significant gastrointestinal disorders that may affect absorption, including (but not limited to) diagnosed bowel obstruction, persistent diarrhea, or the presence of a nasogastric tube (NGT\u002Fzonda)","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"NA","Evaluation of the Effect of metamizole (Optalgin®) on Anti-Xa Levels in Oncology Patients Receiving Direct Oral Anticoagulants (DOACs)",[26,27,28],"Oncologic Diseases","Coagulation Defect","Pain Management",[30,31],"Direct Oral Anticoagulants (DOACs)","Optalgin","RECRUITING","2026-01-26",{"date":35,"type":36},"2026-02-03","ACTUAL",{"date":38,"type":36},"2025-11-01",{"date":40,"type":20},"2027-12-31",{"name":42,"class":43},"Rambam Health Care Campus","OTHER"]